Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038641 | 0.76 | F2 (1.00) | F2PRSS1PRSS2PRSS3HTT | |
| SCHEMBL9805301 | 0.75 | CA1 (0.54) | F2PRSS1PRSS2PRSS3HTT | |
| SCHEMBL9057442 | 0.74 | F2 (0.63) | F2PRSS1PRSS2PRSS3HTT | |
| SCHEMBL30873929 | 0.74 | F2 (0.75) | F2PRSS1PRSS2PRSS3HTT | |
| Guanidine SCHEMBL811270 | 0.74 | CYP2D6 (0.61) | F2PRSS1PRSS2PRSS3HTT | |
| SCHEMBL9858159 | 0.73 | KMT2A (0.49) | F2PRSS1PRSS2PRSS3HTT | |
| SCHEMBL7770967 | 0.73 | F2 (0.55) | F2PRSS1PRSS2PRSS3HTT | |
| SCHEMBL7777272 | 0.73 | F2 (0.55) | F2PRSS1PRSS2PRSS3HTT | |
| SCHEMBL5138891 | 0.72 | F2 (0.59) | F2PRSS1PRSS2PRSS3HTT | |
| Thiourea SCHEMBL1577311 | 0.71 | CYP2D6 (0.58) | F2PRSS1PRSS2PRSS3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | claimed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | claimed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | claimed |
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
| EP-0637318-B1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| US-5686564-A | Peptide derivatives corresponding to the carboxy terminal sequence of hirudin | NOVARTIS CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0693081-A1 | CYCLIC COMPOUNDS AND COMPOSITIONS WHICH INHIBIT BONE RESORPTION | Novartis AG (CH) | 1996-01-24 | — | — | EP | disclosed |
| EP-0637318-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | Novartis AG (CH) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994024153-A1 | CYCLIC COMPOUNDS AND COMPOSITIONS WHICH INHIBIT BONE RESORPTION | CIBA-GEIGY AG (CH) | 1994-10-27 | — | — | WO | disclosed |
| US-5354843-A | Flanking peptides of calcitonin and processes for their manufacture | CIBA-GEIGY CORPORATION (US) | 1994-10-11 | — | — | US | disclosed |
| WO-1993022344-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA-GEIGY AG (CH) | 1993-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | F2 2120/4885PRSS1 2282/4885PRSS2 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.